Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genta Plans Confirmatory Trial To Extend Genasense To First Line CLL Use

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Genta hopes to use a confirmatory trial for Genasense to expand the patient population of the lymphocytic leukemia agent to treatment-naïve patients

You may also be interested in...



Genasense gets standard review for CLL

Genta's Genasense (oblimersen) has a standard review PDUFA date of Oct. 28 for treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL), Genta says March 1. The review designation comes despite Genta's request for a priority review of its NDA, which it submitted Dec. 29, 2005 (1Pharmaceutical Approvals Monthly January 2006, p. 26). The firm highlighted the submission as "the first NDA for a drug that promotes chemotherapy-induced apoptosis in hematologic oncology." Genasense is a first-in-class Bcl-2 protein inhibitor. One of Genta's long-term goals for Genasense is to expand the agent's indications into first-line CLL...

Year-End Submission Rate Stabilizes In 2005 As NDA Approvals Drop

The slow-down in year-end FDA submissions in recent years appears to have stabilized in 2005, with 16 filings in December – up slightly from 13 in December 2004.

Year-End Submission Rate Stabilizes In 2005 As NDA Approvals Drop

The slow-down in year-end FDA submissions in recent years appears to have stabilized in 2005, with 16 filings in December – up slightly from 13 in December 2004.

Topics

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel